<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712944</url>
  </required_header>
  <id_info>
    <org_study_id>L16-079</org_study_id>
    <nct_id>NCT02712944</nct_id>
  </id_info>
  <brief_title>Testosterone Replacement in Renal Failure</brief_title>
  <official_title>Effect of Testosterone Replacement on Erythropoietin Stimulating Agent Use in End Stage Renal Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University Health Sciences Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Tech University Health Sciences Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the effect of testosterone replacement in men with
      renal failure (on dialysis) who also have low testosterone. Specifically, the investigators
      will assess the change in requirement of Erythropoietin Stimulating agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Testosterone replacement can increase hemoglobin count. This can therefore decrease the
      requirement of Erythropoietin Stimulating agents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in dosage of Erythropoietin stimulating agents (ESA)</measure>
    <time_frame>primary outcome will be measured at months 5 and 6.</time_frame>
    <description>Comparison of dose of ESA in the 2 months prior to the start of the drug and in months 5 and 6.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Testosterone intramuscular every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline intramuscular every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testosterone</description>
    <arm_group_label>Testosterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men between ages of 18-80 years of age.

          2. Renal failure on hemodialysis

          3. Free testosterone &lt;5 ng/dl.

          4. Willing to be randomized to intramuscular (IM) testosterone or placebo

          5. Currently getting intravenous Epoetin alfa

        Exclusion Criteria:

          1. Use of testosterone treatment currently or in the past 6 months, including use of over
             the counter androgen containing health supplements.

          2. Congestive heart Failure, class III or IV.

          3. Baseline hemoglobin of &gt; 12 g/dl.

          4. Allergic reactions to testosterone Vehicle (i.e. Peanut oil)

          5. prostate specific antigen&gt;4 ng/ml.

          6. History of Prostate Cancer.

          7. Liver enzymes &gt;twice the upper limit of normal.

          8. HIV or hepatitis C.

          9. Severe untreated obstructive sleep apnea (defined as apnea-hypopnea index&gt; 30).

         10. Subjects on warfarin or other blood thinners.

         11. Active infection (such as foot ulcer)

         12. History of adverse events with testosterone use in past.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Dhindsa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TTUHSC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine J Lovett, RN</last_name>
    <phone>806.743.4433</phone>
    <email>cathy.lovett@ttuhsc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>TTUHSC-Permian Basin</name>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Dhindsa, MBBS</last_name>
      <email>sandeep.dhindsa@ttuhsc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

